Methods and Secondary Outcomes of the Cardioprotection with nebivolol in patients undergoing anthracyclines (CONTROL) trial

Methods and secondary outcomes of the Cardioprotection with nebivolol in patients undergoing anthracyclines (CONTROL) trial.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-10-15
DOI
https://doi.org/10.5281/zenodo.13936700
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Methods and Secondary Outcomes of the Cardioprotection with nebivolol in patients undergoing anthracyclines (CONTROL) trial

Zenodo (CERN European Organization for Nuclear Research)
Chemotherapy-induced cardiotoxicity and mitigation
article

Methods and Secondary Outcomes of the Cardioprotection with nebivolol in patients undergoing anthracyclines (CONTROL) trial

article en

Abstract

Methods and secondary outcomes of the Cardioprotection with nebivolol in patients undergoing anthracyclines (CONTROL) trial.

Zenodo (CERN European Organization for Nuclear Research)
Humanitas University (IT)
Openalex Percentile: Top 47%
Chemotherapy-induced cardiotoxicity and mitigation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Methods and Secondary Outcomes of the Cardioprotection with nebivolol in patients undergoing anthracyclines (CONTROL) trial · Zenodo (CERN European Organization for Nuclear Research) (2024) | TGRS Research Map | TGRS